Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Bicara Therapeutics Inc. (BCAX) had Normalized Pre-Tax Income of $-56.16M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-56.21M |
|
-- |
|
-- |
|
$60.24M |
|
$-60.24M |
|
$4.08M |
|
$-56.16M |
|
|
Normalized Pre-Tax Income |
$-56.16M |
$-56.21M |
|
$-56.21M |
|
$-56.21M |
|
$-56.21M |
|
$-60.24M |
|
$-59.86M |
|
60.72M |
|
60.72M |
|
$-0.93 |
|
$-0.93 |
|
| Balance Sheet Financials | |
$544.91M |
|
$0.35M |
|
$8.68M |
|
$553.60M |
|
$39.34M |
|
-- |
|
$0.30M |
|
$39.64M |
|
$513.96M |
|
$513.96M |
|
$513.96M |
|
65.55M |
|
| Cash Flow Statement Financials | |
$-37.51M |
|
$100.94M |
|
$163.34M |
|
$96.69M |
|
$323.46M |
|
$226.78M |
|
$5.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-37.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.94% |
|
-10.94% |
|
-10.15% |
|
-10.94% |
|
$7.84 |
|
$-0.62 |
|
$-0.62 |
|